Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes
Alessia Castellino(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Grzegorz S. Nowakowski(Université Claude Bernard Lyon 1), Jonathon B. Cohen(Emory University), Jonas Paludo(WinnMed), Thomas M. Habermann(Mayo Clinic in Arizona), Peter Martin(Northwestern University), Matthew J. Maurer(Mayo Clinic in Arizona), Stephen M. Ansell(Mayo Clinic), Susan L. Slager(Mayo Clinic), David J. Inwards(Mayo Clinic), James R. Cerhan(Mayo Clinic), Brian K. Link(University of Iowa), Andrew L. Feldman(Mayo Clinic in Arizona), Umar Farooq(Wake Forest University), Yucai Wang(Mayo Clinic), Melissa C. Larson(Mayo Clinic), Sergei Syrbu(University of Iowa), Cristine Allmer(Mayo Clinic in Arizona), Thomas E. Witzig(WinnMed)
Cited by 23
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents
|The Lancet|2016|2.8k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Body-Mass Index and Mortality among 1.46 Million White Adults
|New England Journal of Medicine|2010|2.3k